CR 3294

Drug Profile

CR 3294

Alternative Names: CR3294

Latest Information Update: 01 Nov 2014

Price : $50

At a glance

  • Originator Rottapharm
  • Developer Rottapharm Madaus
  • Class Anti-inflammatories; Benzamidines; Small molecules
  • Mechanism of Action Metalloprotease inhibitors; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diarrhoea; Inflammatory bowel diseases; Mucositis

Most Recent Events

  • 01 Nov 2014 Phase II development for Diarrhoea, Inflammatory bowel disease and Mucositis is ongoing in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
  • 31 Dec 2009 Phase-I clinical trials in Mucositis in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top